Harvard Bioscience, Inc. (Nasdaq: HBIO) appointed Katherine Eade and Thomas Loewald as Class II directors of the Board of Directors ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE